First Line IRESSA™ Versus Carboplatin/Paclitaxel in Asia

PHASE3CompletedINTERVENTIONAL
Enrollment

1,329

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

April 30, 2008

Study Completion Date

June 30, 2010

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

Gefitinib

oral tablet

DRUG

Carboplatin

IV

DRUG

Paclitaxel

IV

Trial Locations (56)

Unknown

Research Site, Fuzhou

Research Site, Guangzhou

Research Site, Wuhan

Research Site, Nanjing

Research Site, Dalian

Research Site, Chongqing

Research Site, Beijing

Research Site, Chengdu

Research Site, Hangzhou

Research Site, Shanghai

Research Site, Hong Kong

Research Site, Semarang

Research Site, Malang

Research Site, Jakarta

Research Site, Solo

Research Site, Surabaya

Research Site, Yogyakarta

Research Site, Nagoya

Research Site, Okazaki

Research Site, Kashiwa

Research Site, Matsuyama

Research Site, Fukuoka

Research Site, Sapporo

Research Site, Akashi

Research Site, Kobe

Research Site, Kanazawa

Research Site, Yokohama

Research Site, Kumamoto

Research Site, Ōmura

Research Site, Okayama

Research Site, Izumisano

Research Site, Osaka

Research Site, Sakai

Research Site, Sayama

Research Site, Sunto-gun

Research Site, Bunkyo-ku

Research Site, Koto-ku

Research Site, Shinjuku

Research Site, Ube

Research Site, Kota Kinabalu

Research Site, George Town

Research Site, Kampung Baharu Nilai

Research Site, Kuala Lumpur

Research Site, Petaling Jaya

Research Site, Cebu City

Research Site, Manila

Research Site, Quezon City

Research Site, Singapore

Research Site, Changhua

Research Site, Kaohsiung City

Research Site, Taipei

Research Site, Taoyuan District

Research Site, Bangkok

Research Site, Chiang Mai

Research Site, Khon Kaen

Research Site, Songkhla

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY